Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

Diabetes Research and Clinical Practice

Volumn 63, Issue 2, 2004, Pages 127-134

  Jovanovic, Lois ^a   Hassman, David R ^b   Gooch, Brent ^c   Jain, Rajeev ^d   Greco, Susan ^e   Khutoryansky, Naum ^f   Hale, Paula M ^f  

^a SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^b Comprehensive Clinical Research ^*  (United States)

^c Melbourne Internal Medicine Associates   (United States)

^d Advanced Healthcare   (United States)

^e Jacksonville Center for Clinical Research   (United States)

^f NOVO NORDISK INC   (United States)

Author keywords

Combination therapy; Insulin secretagogues; OAD monotherapy failure; Thiazolidinedione

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0347301652     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.09.004     Document Type: Article

References (17)

1. American Diabetes Association, Implications of the United Kingdom Prospective Diabetes Study, Diabetes Care 25(Suppl. 1) (2002) S28-S32.
2. UK Prospective Diabetes Study Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837-853.
3. UK Prospective Diabetes Study Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet 352 (1998) 854-865.
4. Luna B., Feinglos M.N. Oral agents in the management of type 2 diabetes mellitus. Am. Fam. Physician. 63(9):2001;1747-1756.
5. Repaglinide (Prandin) product labeling, 2003.
6. Moses R., Slobodniuk R., Boyages S.et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 22:1999;119-124.
7. Raskin P., Jovanovic L., Berger S., Schwartz S., Woo V., Ratner B. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care. 23:2000;979-983.
8. CDER, Division of Metabolism and Endocrine Drug Products, Draft Guidance, Evaluation of New Treatments for Diabetes Mellitus, 30 September 1997.
9. N.M. Khutoryansky, W.C. Huang, Imputation techniques using SAS software for incomplete data in diabetes clinical trials, Pharmaceutical Industry SAS Users Group Conference Proceedings, Boston, 2001, pp. 334-337.
10. Kipnes M.S., Krosnick A., Rendell M.S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. 111:2001;10-17.
11. Raskin P., McGill J., Hale P., Khutoryansky N. Repaglinide/rosiglitazone combination therapy of type 2 diabetes. Diabetes. 50(Suppl. 2):2001;A128. abstract 516-P.
12. Betteridge D.J. Dyslipidaemia and diabetes. Pract. Diab. Int. 18(6):2001;201-207.
13. Erkelens D.W. Insulin resistance syndrome and type 2 diabetes mellitus. Am. J. Cardiol. 88(Suppl.):2001;38J-42J.
14. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diab. Care. 23(11):2000;1605-1611.
15. Patel J., Anderson R.J., Rappaport E.B. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diab. Obes. Metab. 1:1999;165-172.
16. Mudaliar S., Henry R.R. New Oral Therapies for Type 2 Diabetes Mellitus: The Glitazones or Insulin Sensitizers. Annu. Rev. Med. 52:2001;239-257.
17. Landgraff R., Frank M., Bauer C., Dieken M.L. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int. J. Obes. 24(Suppl. 3):2000;S38-S44.